blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2467156

EP2467156 - COMBINATION THERAPY OF CANCER WITH ANTI-ENDOGLIN ANTIBODIES AND ANTI-VEGF AGENTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  07.09.2018
Database last updated on 03.08.2024
FormerThe patent has been granted
Status updated on  29.09.2017
FormerGrant of patent is intended
Status updated on  20.09.2017
FormerExamination is in progress
Status updated on  18.08.2017
FormerGrant of patent is intended
Status updated on  29.03.2017
FormerExamination is in progress
Status updated on  16.12.2016
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Tracon Pharmaceuticals, Inc.
4350 La Jolla Village Drive
Suite 800
San Diego, CA 92122 / US
For all designated states
Health Research, Inc.
Elm and Carlton Streets
Buffalo, NY 14263 / US
[2017/43]
Former [2012/26]For all designated states
Tracon Pharmaceuticals, Inc.
4510 Executive Drive Suite 330
San Diego, CA 92121 / US
Inventor(s)01 / THEUER, Charles, P.
P.O. Box 90729
San Diego, CA 92169 / US
02 / SEON, Ben K.
204 Ranch Trail West
Williamsville, NY 14221 / US
 [2017/45]
Former [2012/47]01 / THEUER, Charles, P.
2934 Las Olas Court
Carlsbad, CA 92009 / US
02 / SEON, Ben K.
204 Ranch Trail West
Williamsville, NY 14221 / US
Former [2012/26]01 / THEUER, Charles, P.
2934 Las Olas Court
Carlsbad CA 92009 / US
02 / Ben K. Seon
204 Ranch Trail West
Williamsville NY 14221 / US
Representative(s)HGF
8th Floor
140 London Wall
London EC2Y 5DN / GB
[N/P]
Former [2017/44]HGF Limited
8th Floor
140 London Wall
London EC2Y 5DN / GB
Former [2014/26]Longland, Emma Louise, et al
avidity IP
Kestrel House
Falconry Court
Baker's Lane
Epping, Essex CM16 5DQ / GB
Former [2013/03]Blance, Stephen John, et al
Avidity IP
Merlin House
Falconry Court
Baker's Lane
Epping, Essex CM16 5DQ / GB
Former [2012/27]Mannion, Sally Kim, et al
Avidity IP Ltd
Merlin House
Falconry Court
Baker's Lane
Epping, Essex CM16 5DQ / GB
Former [2012/26]Lasterra Sánchez, Elena, et al
avidity IP
Merlin House
Falconry Court
Baker's Lane
Epping, Essex CM16 5DQ / GB
Application number, filing date10810448.016.08.2010
[2017/44]
WO2010US45651
Priority number, dateUS20090234574P17.08.2009         Original published format: US 234574 P
[2012/26]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011022339
Date:24.02.2011
Language:EN
[2011/08]
Type: A1 Application with search report 
No.:EP2467156
Date:27.06.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 24.02.2011 takes the place of the publication of the European patent application.
[2012/26]
Type: B1 Patent specification 
No.:EP2467156
Date:01.11.2017
Language:EN
[2017/44]
Search report(s)International search report - published on:US24.02.2011
(Supplementary) European search report - dispatched on:EP01.03.2013
ClassificationIPC:A61K39/00, C12P21/08, C07K16/22, C07K16/28, C07K16/30
[2013/13]
CPC:
C07K16/22 (EP,US); A61K39/395 (KR); A61P1/00 (EP);
A61P1/04 (EP); A61P13/12 (EP); A61P19/02 (EP);
A61P27/02 (EP); A61P27/12 (EP); A61P29/00 (EP);
A61P3/10 (EP); A61P35/00 (EP); A61P35/04 (EP);
A61P43/00 (EP); A61P9/00 (EP); C07K16/2896 (EP,US);
C07K16/30 (EP,US); C12P21/00 (KR); A61K2039/507 (EP,US);
C07K2317/24 (EP,US); C07K2317/73 (EP,US); C07K2317/76 (EP,US) (-)
Former IPC [2012/26]A61K39/00, C12P21/08
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/26]
Extension statesBANot yet paid
MENot yet paid
RSNot yet paid
TitleGerman:KOMBINATIONS-KREBSTHERAPIE MIT ANTI-ENDOGLIN-ANTIKÖRPERN UND ANTI-VEGF-MITTELN[2012/26]
English:COMBINATION THERAPY OF CANCER WITH ANTI-ENDOGLIN ANTIBODIES AND ANTI-VEGF AGENTS[2012/26]
French:POLYTHÉRAPIE DU CANCER AU MOYEN D ANTICORPS ANTI-ENDOGLINE ET D AGENTS ANTI-VEGF[2012/26]
Entry into regional phase09.03.2012National basic fee paid 
09.03.2012Search fee paid 
09.03.2012Designation fee(s) paid 
09.03.2012Examination fee paid 
Examination procedure09.03.2012Examination requested  [2012/26]
26.09.2013Amendment by applicant (claims and/or description)
26.02.2014Despatch of a communication from the examining division (Time limit: M04)
18.06.2014Reply to a communication from the examining division
25.08.2015Despatch of a communication from the examining division (Time limit: M06)
08.02.2016Reply to a communication from the examining division
06.12.2016Despatch of a communication from the examining division (Time limit: M02)
19.12.2016Reply to a communication from the examining division
30.03.2017Communication of intention to grant the patent
08.08.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
08.08.2017Fee for grant paid
08.08.2017Fee for publishing/printing paid
20.09.2017Information about intention to grant a patent
20.09.2017Receipt of the translation of the claim(s)
Divisional application(s)EP14151471.1  / EP2722055
EP17194562.9  / EP3281637
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  26.02.2014
Opposition(s)02.08.2018No opposition filed within time limit [2018/41]
Fees paidRenewal fee
27.08.2012Renewal fee patent year 03
19.08.2013Renewal fee patent year 04
13.08.2014Renewal fee patent year 05
27.08.2015Renewal fee patent year 06
29.08.2016Renewal fee patent year 07
28.08.2017Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU16.08.2010
AL01.11.2017
AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
FI01.11.2017
HR01.11.2017
LT01.11.2017
LV01.11.2017
MC01.11.2017
MK01.11.2017
NL01.11.2017
PL01.11.2017
PT01.11.2017
RO01.11.2017
SE01.11.2017
SI01.11.2017
SK01.11.2017
SM01.11.2017
TR01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IS01.03.2018
[2020/33]
Former [2020/31]HU16.08.2010
AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
FI01.11.2017
HR01.11.2017
LT01.11.2017
LV01.11.2017
MC01.11.2017
MK01.11.2017
NL01.11.2017
PL01.11.2017
PT01.11.2017
RO01.11.2017
SE01.11.2017
SI01.11.2017
SK01.11.2017
SM01.11.2017
TR01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IS01.03.2018
Former [2020/27]HU16.08.2010
AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
FI01.11.2017
HR01.11.2017
LT01.11.2017
LV01.11.2017
MC01.11.2017
NL01.11.2017
PL01.11.2017
PT01.11.2017
RO01.11.2017
SE01.11.2017
SI01.11.2017
SK01.11.2017
SM01.11.2017
TR01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IS01.03.2018
Former [2020/16]AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
FI01.11.2017
HR01.11.2017
LT01.11.2017
LV01.11.2017
MC01.11.2017
NL01.11.2017
PL01.11.2017
RO01.11.2017
SE01.11.2017
SI01.11.2017
SK01.11.2017
SM01.11.2017
TR01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IS01.03.2018
Former [2019/15]AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
FI01.11.2017
HR01.11.2017
LT01.11.2017
LV01.11.2017
MC01.11.2017
NL01.11.2017
PL01.11.2017
RO01.11.2017
SE01.11.2017
SI01.11.2017
SK01.11.2017
SM01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IS01.03.2018
Former [2018/52]AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
FI01.11.2017
HR01.11.2017
LT01.11.2017
LV01.11.2017
NL01.11.2017
PL01.11.2017
RO01.11.2017
SE01.11.2017
SI01.11.2017
SK01.11.2017
SM01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IS01.03.2018
Former [2018/40]AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
FI01.11.2017
HR01.11.2017
LT01.11.2017
LV01.11.2017
NL01.11.2017
PL01.11.2017
RO01.11.2017
SE01.11.2017
SK01.11.2017
SM01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IS01.03.2018
Former [2018/37]AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
FI01.11.2017
HR01.11.2017
LT01.11.2017
LV01.11.2017
NL01.11.2017
PL01.11.2017
SE01.11.2017
SK01.11.2017
SM01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IS01.03.2018
Former [2018/35]AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
FI01.11.2017
HR01.11.2017
LT01.11.2017
LV01.11.2017
NL01.11.2017
SE01.11.2017
SK01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IS01.03.2018
Former [2018/24]AT01.11.2017
FI01.11.2017
HR01.11.2017
LT01.11.2017
LV01.11.2017
NL01.11.2017
SE01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IS01.03.2018
Former [2018/23]AT01.11.2017
FI01.11.2017
HR01.11.2017
LT01.11.2017
NL01.11.2017
SE01.11.2017
NO01.02.2018
GR02.02.2018
IS01.03.2018
Former [2018/22]FI01.11.2017
LT01.11.2017
NL01.11.2017
NO01.02.2018
Documents cited:Search[A]US928641  (EDMUNDS LEVI E [US]) [A] 1-15 * the whole document *;
 [A]US2009142343  (FUH GERMAINE [US], et al) [A] 1-15* the whole document *;
 [XI]  - Rosen, L. S., "EARLY EVIDENCE OF TOLERABILITY AND CLINICAL ACTIVITY FROM A PHASE 1 STUDY OFTRC105 (ANT-CD105 ANTIBODY) IN PATIENTS WITH ADVANCED REFRACTORY CANCER", (20090602), 2009 ASCO Annual Meeting, URL: http://www.traconpharma.com/pdfs/105ST101_TRC105_EORTC_NCI_AACR_Poster.pdf, (20130211), XP002692012 [X] 1-9,11,13 * the whole document * [I] 10,12,14,15
 [A]  - Tracon Pharmaceuticals, "TRACON Pharmaceuticals Announces Dosing of Initial Three Cancer Patients in a Phase 1 Clinical Trial with TRC105, a Human Chimeric AntibodyTRACON Pharmaceuticals Announces Dosing of Initial Three Cancer Patients in a Phase 1 Clinical Trial with TRC105, a Human Chimeric Antibody", (20080108), Company News, URL: http://www.traconpharma.com/content/pr_01_9_08.html, (20130212), XP002692013 [A] 1-15 * the whole document *
International search[A]US2003129193  (THORPE PHILIP E [US], et al);
 [A]US2004023313  (BOYLE WILLIAM J [US], et al);
 [A]US2006292643  (GOLETZ STEFFEN [DE], et al);
 [A]US2007072797  (ROBINSON MARTYN K [GB], et al)
Examination   - SHIMA UNEDA ET AL, "Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature", INTERNATIONAL JOURNAL OF CANCER, (20090915), vol. 125, no. 6, doi:10.1002/ijc.24482, ISSN 0020-7136, pages 1446 - 1453, XP055208365

DOI:   http://dx.doi.org/10.1002/ijc.24482
by applicantUS4816567
 EP0404097
 WO9311161
 US5391377
 US5756097
 US5928641
 US6190660
 US6200566
 US6350861
 US6610293
 US6737056
 US2004175756
 US2005037421
 US2005048512
 US2005053973
 US2005089932
 US2005164301
 US2005221384
 US7091321
 US7097836
 US2007082380
 US7217798
    - KABAT ET AL., Sequences of Proteins of Immunological Interest, NATIONAL INSTITUTES OF HEALTH, (1991), pages 647 - 669
    - CHOTHIA; LESK, J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - WARD ET AL., NATURE, (1989), vol. 341, pages 544 - 2005
    - REITER ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 1239 - 1245
    - BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426
    - HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 5883
    - OSBOURN ET AL., NAT. BIOTECHNOL., (1998), vol. 16, page 778
    - PLUCKTHUN, The Pharmacology of Monoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315
    - SILVERMAN ET AL., NAT. BIOTECHNOL., (2005), vol. 23, pages 1493 - 1494
    - SILVERMAN ET AL., NAT. BIOTECHNOL., (2006), vol. 24, page 220
    - HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
    - MUYLDERMANS ET AL., PROTEIN ENGINEERING, (1994), vol. 7, no. 9, page 1129
    - JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525
    - REICHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329
    - PRESTA, CURR. OP. STRUCT. BIOL., (1992), vol. 2, pages 593 - 596
    - KOHLER ET AL., NATURE, (1975), vol. 256, page 495
    - CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628
    - MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 597
    - PLUCKTHUN, A., BIO/TECHNOLOGY, (1991), vol. 9, pages 545 - 551
    - RAFF, M.E., CURR. OPINION BIOTECH, (1993), vol. 4, pages 573 - 576
    - TRILL J.J. ET AL., CURR. OPINION BIOTECH, (1995), vol. 6, pages 553 - 560
    - EDGE, NATURE, (1981), vol. 292, page 756
    - NAMBAIR ET AL., SCIENCE, (1984), vol. 223, page 1299
    - JAY ET AL., J. BIOL. CHEM., (1984), vol. 259, page 6311
    - DUFF ET AL., FASEB J., (2003), vol. 17, pages 984 - 992
    - HARUTA; SEON, PROC. NATL. ACAD. SCI., (1986), vol. 83, pages 7898 - 7902
    - GOUGOS; LETARTE, J. IMMUNOL., (1988), vol. 141, pages 1925 - 1933
    - J. BIOL. CHEM., (1990), vol. 265, pages 8361 - 8364
    - BURROWS ET AL., CLIN. CANCER RES., (1995), vol. 1, pages 1623 - 1634
    - LEUNG ET AL., SCIENCE, (1989), vol. 246, page 1306
    - HOUCK ET AL., MOL. ENDOCRIN., (1991), vol. 5, page 1806
    - PRESTA ET AL., CANCER RES., (1997), vol. 57, pages 4593 - 4599
    - GHETIE ET AL., PHARMACOL. THER., (1994), vol. 63, pages 209 - 234
    - FRANCIS ET AL., INTERNATIONAL JOURNAL OF HEMATOLOGY, (1998), vol. 68, pages 1 - 18
    - LEATHERBARROW ET AL., MOL. IMMUNOL., (1985), vol. 22, page 407
    - TAO; MORRISON, J. IMMUNOL., (1989), vol. 143, page 2595
    - MURAOKA; SHULMAN, J. IMMUNOL., (1989), vol. 142, page 695
    - TAYLOR; WALL, MOL. CELL. BIOL., (1988), vol. 8, page 4197
    - PROC. NATL. ACAD. SCI. USA, (1970), vol. 66, page 975
    - LILJEBLAD ET AL., GLYCO. J., (2000), vol. 17, pages 323 - 329
    - HEELEY, R. P., ENDOCR. RES., (2002), vol. 28, pages 217 - 229
    - LAHN ET AL., "Aerosolized Anti-T- cell-Receptor Antibodies Are Effective against Airway Inflammation and Hyperreactivity", INT. ARCH. ALLEGERY IMMUNO., (2004), vol. 134, doi:doi:10.1159/000077533, pages 49 - 55, XP009073464

DOI:   http://dx.doi.org/10.1159/000077533
    - FIX, PHARM RES., (1996), vol. 13, pages 1760 - 1764
    - SAMANEN, J. PHARM. PHARMACOL., (1996), vol. 48, pages 119 - 135
    - CHIDLOW ET AL., AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL., (2007), vol. 293, pages 5 - 18
    - ALTMAN, R ET AL., ARTHRITIS RHEUM, (1991), vol. 34, page 505
    - ALTMAN, R ET AL., ARTHRITIS RHEUM, (1986), vol. 29, page 1039
    - KIM ET AL., BREAST CANCER RESEARCH TREATMENT, (2004), vol. 85, no. 3, pages 281 - 291
    - TSUJIE ET AL., INT. J. ONCOLOGY, (2006), vol. 29, pages 1087 - 1094
    - YAN ET AL., J. CLIN. INVEST., (1993), vol. 91, pages 986 - 996
    - D'AMATO ET AL., PROC. NATL. ACAD. SCI. USA, (1994), vol. 91, no. 9, pages 4082 - 4085
    - MONTESANO ET AL., J. CELL BIOL., (1983), vol. 97, pages 1648 - 1652
    - STEFANSSON ET AL., J. BIOL. CHEM., (2000), vol. 276, pages 8135 - 8141
    - FURSTENBERGER ET AL., LANCET, (2002), vol. 3, pages 298 - 302
    - VOLPERT ET AL., CANCER CELL, (2002), vol. 2, no. 6, pages 473 - 483
    - SU ET AL., CANCER RES., (2003), vol. 63, pages 3585 - 3592
    - SCHNAPER ET AL., J. CELL PHYSIOL., (1993), vol. 256, pages 235 - 246
    - GIGLI ET AL., J. IMMUNOL., (1986), vol. 100, pages 1154 - 1164
    - BROOKS ET AL., J. CLIN. INVEST, (1997), vol. 99, pages 1390 - 1398
    - SHE ET AL., INT. J. CANCER, (2004), vol. 108, pages 251 - 257
    - A. H. GREENBERG ET AL., "Characteristics Of The Effector Cells Mediating Cytotoxicity Against Antibody-Coated Target Cells", IMMUNOLOGY, (1975), vol. 21, page 719
    - I. C. M. MACLENNAN, "Competition For Receptors For Immunoglobulin On Cytotoxic Lymphocytes", CLIN. EXP. IMMUNOL., (1972), vol. 10, page 275
    - J. F. JONES; D. M. SEGAL, "Antibody-Dependent Cell Mediated Cytolysis (ADCC) With Antibody-Coated Effectors: New Methods For Enhancing Antibody Binding And Cytolysis", J. IMMUNOL., (1980), vol. 125, pages 926 - 933
    - I. R. MACKAY ET AL., "Effect On Natural Killer And Antibody-Dependent Cellular Cytotoxicity Of Adjuvant Cytotoxic Chemotherapy Including Melphalan In Breast Cancer", CANCER IMMUNOL. IMMUNOTHER, (1983), vol. 16, pages 98 - 100
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.